Masteronum 100 - Magnum Laboratories

First approved for medical use in the 1970s, drostanolone propionate was introduced as a hormonal therapy for breast cancer. Created by Syntex, and marketed in the U.S. as Drolban, it offered clinicians a DHT-derived compound with anti-estrogenic effects and low androgenicity. The drug’s ability to limit estrogen activity without converting to it made it valuable in female oncology. Later, it became a favorite among athletes for enhancing muscular hardness, vascularity, and definition—especially during cutting phases.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Masteronum 100 by Magnum Laboratories, consult with your doctor or healthcare professional.